<DOC>
	<DOC>NCT02670603</DOC>
	<brief_summary>This study is a prospective randomized controlled study of EVONAIL® solution for prevention or treatment of onycholysis in patients with breast cancer receiving docetaxel chemotherapy.</brief_summary>
	<brief_title>A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Onycholysis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Patients with breast cancer receiving adjuvant/neoadjuvant docetaxel chemotherapy Patients with breast cancer receiving palliative docetaxel chemotherapy Patients having onycholysis before docetaxel treatment</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>